Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors

[1]  K. Oka,et al.  Decitabine, a DNA methyltransferase inhibitor, reduces P-glycoprotein mRNA and protein expressions and increases drug sensitivity in drug-resistant MOLT4 and Jurkat cell lines. , 2012, Anticancer research.

[2]  Robert Brown,et al.  Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling , 2012, Oncogene.

[3]  V. Labhasetwar,et al.  Epigenetic modulation of the biophysical properties of drug-resistant cell lipids to restore drug transport and endocytic functions. , 2012, Molecular pharmaceutics.

[4]  D. Matei,et al.  Epigenetic resensitization to platinum in ovarian cancer. , 2012, Cancer research.

[5]  M. Diederich,et al.  DNA demethylation increases sensitivity of neuroblastoma cells to chemotherapeutic drugs. , 2012, Biochemical pharmacology.

[6]  T. Utsunomiya,et al.  Demethylation restores SN38 sensitivity in cells with acquired resistance to SN38 derived from human cervical squamous cancer cells , 2012, Oncology reports.

[7]  R. Singal,et al.  5-azacytidine reverses drug resistance in bladder cancer cells. , 2011, Anticancer research.

[8]  Y. Sekine,et al.  A demethylating agent enhances chemosensitivity to vinblastine in a xenograft model of renal cell carcinoma. , 2011, International journal of oncology.

[9]  R. Bast,et al.  Phase 1b‐2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum‐resistant or platinum‐refractory epithelial ovarian cancer , 2011, Cancer.

[10]  D. Matei,et al.  A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum‐resistant, epithelial ovarian cancer , 2010, Cancer.

[11]  D. Stewart.  Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. , 2010, Critical reviews in oncology/hematology.

[12]  David Sidransky,et al.  Identification of hypermethylated genes associated with cisplatin resistance in human cancers. , 2010, Cancer research.

[13]  J. Sprowl,et al.  The temporal relationship between ABCB1 promoter hypomethylation, ABCB1 expression and acquisition of drug resistance , 2010, The Pharmacogenomics Journal.

[14]  T. Byers,et al.  Multivitamins, folate, and green vegetables protect against gene promoter methylation in the aerodigestive tract of smokers. , 2010, Cancer research.

[15]  K. Tikoo,et al.  5-Azacytidine prevents cisplatin induced nephrotoxicity and potentiates anticancer activity of cisplatin by involving inhibition of metallothionein, pAKT and DNMT1 expression in chemical induced cancer rats. , 2009, Toxicology letters.

[16]  R. Singal,et al.  Methylation mediated silencing of TMS1 in breast cancer and its potential contribution to docetaxel cytotoxicity. , 2009, Anticancer research.

[17]  E. Giovannetti,et al.  Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines , 2009, Molecular Cancer Therapeutics.

[18]  J. Martinez-Climent,et al.  Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia. , 2009, European journal of cancer.

[19]  D. Shang,et al.  Synergy of 5-aza-2'-deoxycytidine (DAC) and paclitaxel in both androgen-dependent and -independent prostate cancer cell lines. , 2009, Cancer letters.

[20]  Lili Ding,et al.  Camptothecin-induced cell proliferation inhibition and apoptosis enhanced by DNA methyltransferase inhibitor, 5-aza-2'-deoxycytidine. , 2009, Biological & pharmaceutical bulletin.

[21]  Vincenza Dolo,et al.  Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models. , 2009, Endocrine-related cancer.

[22]  I. Wistuba,et al.  Decitabine Effect on Tumor Global DNA Methylation and Other Parameters in a Phase I Trial in Refractory Solid Tumors and Lymphomas , 2009, Clinical Cancer Research.

[23]  R. Srinivasan,et al.  Effect of c-MYC and E2F1 Gene Silencing and of 5-Azacytidine Treatment on Telomerase Activity in Pancreatic Cancer-Derived Cell Lines , 2009, Pancreatology.

[24]  R. Broaddus,et al.  DNA methylation inhibits p53-mediated survivin repression , 2009, Oncogene.

[25]  H. Ngan,et al.  Epigenetic Alteration of the Metallothionein 1E Gene in Human Endometrial Carcinomas , 2009, Tumor Biology.

[26]  S. Mateos,et al.  DNA demethylation protects from cleavable complex stabilization and DNA strand breakage induced by the topoisomerase type I inhibitor camptothecin. , 2009, Mutagenesis.

[27]  Ye Zhang,et al.  GSTP1 determines cis-platinum cytotoxicity in gastric adenocarcinoma MGC803 cells: regulation by promoter methylation and extracellular regulated kinase signaling , 2009, Anti-cancer drugs.

[28]  Wei Hu,et al.  Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis. , 2009, American journal of obstetrics and gynecology.

[29]  R. Kurzrock,et al.  Cancer: the road to Amiens. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  M. Tsao,et al.  Role of myofibroblasts in innate chemoresistance of pancreatic carcinoma—Epigenetic downregulation of caspases , 2008, International journal of cancer.

[31]  M. Akabas,et al.  The Proton-Coupled Folate Transporter: Impact on Pemetrexed Transport and on Antifolates Activities Compared with the Reduced Folate Carrier , 2008, Molecular Pharmacology.

[32]  J. Issa,et al.  Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. , 2008, Blood.

[33]  C. Choi,et al.  Epigenetic mechanisms involved in differential MDR1 mRNA expression between gastric and colon cancer cell lines and rationales for clinical chemotherapy , 2008, BMC gastroenterology.

[34]  M. Gonen,et al.  Immunohistochemical expression of folate receptor alpha in colorectal carcinoma: patterns and biological significance. , 2008, Human pathology.

[35]  Xiao-Nan Li,et al.  Relationship between methylation status of ERCC1 promoter and radiosensitivity in glioma cell lines , 2008, Cell biology international.

[36]  D. Stewart,et al.  Mechanisms of resistance to cisplatin and carboplatin. , 2007, Critical reviews in oncology/hematology.

[37]  Shoumei Bai,et al.  DNA methyltransferases as targets for cancer therapy. , 2007, Drugs of today.

[38]  S. Dahrouge,et al.  Chemotherapy dose--response relationships in non-small cell lung cancer and implied resistance mechanisms. , 2007, Cancer treatment reviews.

[39]  O. Kovalchuk,et al.  Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets , 2007, Molecular Cancer Therapeutics.

[40]  J. Issa,et al.  Decitabine--bedside to bench. , 2007, Critical reviews in oncology/hematology.

[41]  E. Zabarovsky,et al.  Activation of RHOA transcription in epithelial tumors may be caused by gene amplification and/or demethylation of the promoter region , 2006, Molecular Biology.

[42]  J. Issa,et al.  Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Y. Shim,et al.  Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung. , 2004, Carcinogenesis.

[44]  M. Gottesman,et al.  A pleiotropic defect reducing drug accumulation in cisplatin-resistant cells. , 2004, Journal of inorganic biochemistry.

[45]  M. Gottesman,et al.  Reduced expression of small GTPases and hypermethylation of the folate binding protein gene in cisplatin-resistant cells , 2004, British Journal of Cancer.

[46]  Jorge Cortes,et al.  Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. , 2004, Blood.

[47]  J. Issa,et al.  A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. , 2004, Nucleic acids research.

[48]  Y. Assaraf,et al.  Reduced Folate Carrier Gene Silencing in Multiple Antifolate-resistant Tumor Cell Lines Is Due to a Simultaneous Loss of Function of Multiple Transcription Factors but Not Promoter Methylation* , 2004, Journal of Biological Chemistry.

[49]  I. Pogribny,et al.  DNA methylation in Folbp1 knockout mice supplemented with folic acid during gestation. , 2002, The Journal of nutrition.

[50]  J. Moscow,et al.  Down-regulation of reduced folate carrier gene (RFC1) expression after exposure to methotrexate in ZR-75-1 breast cancer cells. , 2000, Biochemical and biophysical research communications.

[51]  J. Sludden,et al.  Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. , 2000, Cancer research.

[52]  D. Heimburger,et al.  Localized Folate and Vitamin B-12 Deficiency in Squamous Cell Lung Cancer Is Associated With Global DNA Hypomethylation , 2000, Nutrition and cancer.

[53]  Francesco Onida,et al.  Faculty of 1000 evaluation for Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. , 2012 .

[54]  J. Issa,et al.  Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. , 2007, Blood.

[55]  E. Klimov,et al.  [Activation of RHOA gene transcription in epithelial tumors may be caused by gene amplification and/or demethylation of its promotor region]. , 2006, Molekuliarnaia biologiia.

[56]  M. Kane.  The role of folates in squamous cell carcinoma of the head and neck. , 2005, Cancer detection and prevention.

[57]  G. Raaphorst,et al.  Active vs. passive resistance, dose-response relationships, high dose chemotherapy, and resistance modulation: a hypothesis , 2004, Investigational New Drugs.

[58]  J. Herman,et al.  Alterations in DNA methylation: a fundamental aspect of neoplasia. , 1998, Advances in cancer research.